DEPRENYL, A THERAPEUTIC AGENT FOR PARKINSON'S DISEASE, INHIBITS ARSENIC TOXICITY POTENTIATED BY GSH DEPLETION VIA INHIBITION OF JNK ACTIVATION

Author： Kim Sang   Lee Chang   Park Jeong  

Publisher： Taylor & Francis Ltd

ISSN： 1087-2620

Source： Journal of Toxicology and Environmental Health, Vol.67, Iss.23-24, 2004-12, pp. : 2013-2024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of Selegiline (Deprenyl) in the Treatment of Parkinson's Disease

By Heinonen E.H.  

Drug Safety, Vol. 19, Iss. 1, 1998-07 ,pp. : 11-22

Adis International

Access to resources Recommend Favorite

C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 17, Iss. 1, 2018-04 ,pp. : 14-21

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 1, 2014-02 ,pp. : 120-125

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 1, Iss. 1, 2002-02 ,pp. : 31-49

Bentham Science Publishers

Access to resources Recommend Favorite

Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Iss. 4, 2004-12 ,pp. : 255-267

Bentham Science Publishers

Access to resources Recommend Favorite